BIOTHRAX

This brand name is authorized in United States. It is also authorized in Poland, Singapore, UK.

Active ingredients

The drug BIOTHRAX contains one active pharmaceutical ingredient (API):

1	Anthrax antigen UNII 873OI62848 - BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS
	Anthrax antigen induces antibodies raised against PA that may contribute to protection by neutralizing the activities of the cytotoxic lethal toxin and edema toxin of Bacillus anthracis.
	Read more about Anthrax antigen

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BIOTHRAX Suspension for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07AC01	Anthrax antigen	J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines → J07AC Anthrax vaccines
Discover more medicines within J07AC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
GB	Medicines & Healthcare Products Regulatory Agency	368315, 368316
PL	Rejestru Produktów Leczniczych	100397951
SG	Health Sciences Authority	13967P
US	FDA, National Drug Code	64678-211